Full-Time
Controls Engineer / Process Development & Automation Engineer 2
Posted on 11/23/2025
Exact Sciences
5,001-10,000 employees
Develops cancer screening and diagnostic tests
Compensation Overview
$74k - $122k/yr
Company Does Not Provide H1B Sponsorship
Madison, WI, USA
In Person
Travel approx. 10% for training, vendor site visits, and inter-site travel.
 Biology & Biotech (2) |
|---|
| , |
- Bachelor’s degree in Engineering or related field; or Associates degree in Engineering, Technology, Electronics, or similar field with 2 years of relevant industry experience.
- Possesses basic knowledge of engineering theories, practices and procedures and applies this knowledge and skills to complete assignments.
- Authorization to work in the United States without sponsorship.
- Demonstrated ability to perform the Essential Duties of the position with or without accommodation.
- Applies defined protocols and procedures; conducts moderate level testing activities and data analysis. Applies technical knowledge to develop company products and to recommend product enhancements.
- Able to troubleshoot anomalies.
- Conducts moderately complex engineering design, platform eligibility testing, systems integration, or performance testing.
- Able to train others on the proper use of Exact Sciences equipment.
- Exercises independent judgment within generally defined practices and procedures in selecting methods and techniques of obtaining solutions.
- Able to recognize need for deviation.
- Scenario based decision making.
- Able to present, organize and convey problems or issues across functional areas within the same product line/platform/business organization.
- Assists in preparing information for design documentation and design reviews.
- Contributes as team member to meet pre-defined goals.
- Encourages team participation.
- Learning and building knowledge of products, company, business, and industry.
- Understands individual impact to company work processes and deliverables.
- Work with project managers and cross-functional teams on user requirements, factory acceptance tests, validation planning, site acceptance tests, pre-installation planning, initial installation, setup, maintenance, and improvement for new or upgraded instrumentation and automation systems.
- Independently address routine issues utilizing documented procedures and researching historical cases.
- Recommend and implement changes to ensure ongoing high-quality performance of laboratory equipment.
- Assist in technical investigation and troubleshooting of laboratory systems.
- Ensure both new and existing instrumentation automation and non-automation meet safety requirements and compliance standards.
- Maintain records and follow laboratory procedures to meet regulatory requirements such as FDA, CLIA, and/or CAP.
- Maintain and continuously develop personal knowledge and expertise related to the programming, implementation and service of complex clinical laboratory equipment.
- Excellent verbal and written English communication skills.
- Ability to define problems, collect data, establish facts, and draw data driven conclusions.
- Have demonstrated ability to follow procedures and maintain detailed records.
- Have demonstrated ability to manage time and competing priorities.
- Must be highly motivated and able to work both independently and as a member of a team.
- Adaptable, open to change and able to work in ambiguous situations and respond to new information and unexpected circumstances.
- Proven capability to take scientific bench protocols from the bench to automation system.
- Effectively communicate issues/problems and results that impact timelines, accuracy, and reliability of data.
- A wide degree of creativity and latitude is expected including the ability to multi-task and work productively in a demanding environment with changing priorities.
- Uphold company mission and values through accountability, innovation, integrity, quality, and teamwork.
- Support and comply with the company’s Quality Management System policies and procedures.
- Regular and reliable attendance.
- Occasional evening and weekend work may be required.
- Ability to lift up to 50 pounds for < 5% of a typical working day.
- Ability to work seated for approximately 80% of a typical working day.
- Ability to work standing for approximately 20% of a typical working day.
- Ability to work in front of a computer screen and/or perform typing for approximately 80% of a typical working day.
- Ability to comply with all applicable personal protective equipment requirements.
- Ability to travel approximately 10% of working time for occasional training, out of state vendor site visits, and travel between Exact Sciences sites.
- Bachelor’s degree in Engineering or related field and 3 years of relevant industry experience; or Associates degree in Engineering, Technology, Electronics, or similar field with 5 years of relevant industry experience.
- 2-3 years custom automation controls related experience, including but not limited to ladder logic programming with Rockwell Studio 5000.
- Technical proficiency and experience in automation and system development and integration in a laboratory environment.
- Experience working in a CAP/CLIA and/or other regulated production environment.
- Working knowledge of database, laboratory information management systems, and other file management applications.
- SCADA/MES system and integration knowledge.
- Program troubleshooting and triage.
- Automation vision system programming, adjustment and troubleshooting.
- Working knowledge of HMI programming software.
- Custom automation network integration.
Exact Sciences develops and sells cancer screening and diagnostic tests that aim to detect cancer at its earliest stages and inform treatment decisions. The tests are designed to analyze biological samples to identify cancer signals, enabling healthcare providers to screen patients, diagnose cancer earlier, and tailor therapies accordingly. The company differentiates itself through its global reach, collaborations with healthcare organizations, and a business model that centers on test sales and partnerships, not just standalone products. Its goal is to reduce the burden of cancer by improving early detection, enabling timely interventions, and supporting patients and clinicians with diagnostic information.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Madison, Wisconsin
Founded
1995
Simplify's Take
What believers are saying
- Abbott merger closed March 23, 2026, adds $3B sales.
- Walgreens partnership expands Cologuard via pharmacies nationwide.
- Cancerguard advances multi-cancer early detection pipeline.
What critics are saying
- Abbott integration delays Oncotype DX advancements, cuts growth 10-15%.
- EPS dilution forces $75M Freenome R&D cuts, loses to Guardant.
- Cultural clashes erase Exact Sciences brand, drops Oncotype preference 25%.
What makes Exact Sciences unique
- Cologuard leads noninvasive colorectal cancer screening market.
- Oncotype DX guides early-stage breast cancer treatment decisions.
- Oncodetect detects MRD in triple-negative breast cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Wellness Program
Stock Options
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 8%2 year growth
↑ 8%Exact Sciences broadens evidence for Oncodetect MRD test in early triple-negative breast cancer. SAN DIEGO - Exact Sciences, now part of Abbott, is continuing to build the evidence base supporting the use of its Oncodetect minimal residual disease (MRD) test in early-stage triple-negative breast cancer patients by demonstrating its ability to assess who is unlikely to achieve pathologic complete response after neoadjuvant treatment and at risk of distant recurrence. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month
Abbott acquisition of Exact Sciences set to close on March 23, 2026. * Announcement follows receipt of all regulatory clearances necessary for closing * Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ - Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages. "Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework," said Robert B. Ford, chairman and chief executive officer, Abbott. "The addition of Exact Sciences enhances Abbott's growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health." Strategic fit Exact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence. This acquisition strengthens Abbott's leadership position and capabilities in diagnostics, positioning the company to advance technologies that are more preventative, predictive and personalized. It expands Abbott's presence in one of the fastest-growing areas of healthcare as cancer incidence continues to rise worldwide. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. Industry-leading offerings and pipeline Exact Sciences' product offerings include the Cologuard(R) test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX(R), which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect(R), a tumor informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard(R), a multi-cancer early detection blood test. Exact Sciences is also advancing a leading pipeline of next-generation cancer diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage disease. Financial As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share (EPS) by approximately $0.20. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. Forward-Looking Statements This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties' definitive agreement for the proposed transaction; the ability of Abbott to successfully integrate Exact Sciences' operations, and the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the proposed transaction; risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; risks related to the ability of Abbott to realize the anticipated synergies and benefits of the proposed transaction, including the possibility that the expected synergies and benefits from the proposed transaction will not be realized or will not be realized within the expected time period; potential adverse effects of the announcement or pendency of the proposed transaction; or any failure to complete the proposed transaction on the market price of Abbott's common stock, on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences' ability to attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business, or otherwise on Exact Sciences' or Abbott's business, financial condition, results of operations and financial performance; risks related to diversion of management's attention from Exact Sciences' ongoing business operations due to the proposed transaction; and the risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business and the outcome of any such litigation or regulatory action. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the "Risk Factors" section in each of Abbott's Annual Report on Form 10-K for the year ended December 31, 2025, and Exact Sciences' Annual Report on Form 10-K for the year ended December 31, 2025, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law. SOURCE Abbott For further information: Abbott Media: Scott Stoffel, (224) 668-5201, Abbott Financial: Michael Comilla, (224) 668-1872
Workflow Services supports Walgreens national Colorectal Cancer initiative to close screening gaps; leverages Cologuard(R) tests to expand reach. PR Newswire Today at 9:39pm PDT PR Newswire MADISON, Wis., March 13, 2026 MADISON, Wis., March 13, 2026 /PRNewswire/ - Beginning today, Walgreens customers can access tools and resources to better understand their colorectal cancer screening options - including a streamlined pathway that enables eligible, average-risk patients to request screening with the Cologuard(R) test. In recognition of Colorectal Cancer Awareness Month and to help remove barriers to screening and support earlier detection of colorectal cancer, when it is most treatable, Walgreens is working to increase awareness of non-invasive screening options by teaming up with Exact Sciences, the maker of Cologuard, and Workflow Services, a pharmacy clinical workflow platform that integrates screening programs directly into pharmacy operations. Colorectal cancer is often called a "silent" disease because it frequently develops without symptoms. It is expected to claim more than 55,000 lives in the U.S. this year alone and has become the #1 cause of cancer death in adults under 50.[1,2] Colorectal cancer is also highly preventable.[3] Screening for colorectal cancer can help find pre-cancerous growths (polyps) so they can be removed before they turn into cancer. When caught in its early stages, the five-year survival rate is 91%.[4] Unfortunately, more than 1 in 3 U.S. adults are not up to date with colorectal screening.[5] By launching this program, Walgreens is taking an important step toward closing the screening gap and supporting earlier detection for millions of Americans. The Cologuard test is an FDA-approved, non-invasive stool DNA test to screen adults 45 and older at average risk for colorectal cancer. It offers an effective way to screen from home, requiring no special diet, no prep, and no time away from work. It is also covered by most insurance companies, including Medicare and Medicaid. "As a trusted health partner in the community, we have a unique opportunity to change the trajectory of this disease," said Rick Gates, Chief Pharmacy Officer, Walgreens. "We are offering eligible patients' education around their colon cancer screening options and giving them access to take action. Use-at-home stool-based tests like Cologuard allow customers to prioritize their health in a convenient way. By making screening a seamless part of the pharmacy experience, we are helping our patients take proactive, life-saving action." Workflow Services, a software platform to support clinical service delivery in pharmacies, has partnered with Walgreens and Exact Sciences to bring a nationwide colorectal cancer screening program to close care gaps for their customers. As pharmacies continue to evolve into important access points for clinical services, Workflow Services is proud to help enable scalable, pharmacist-led care programs that improve patient access and health outcomes. Access to preventative screenings is just another way Walgreens serves as a connector between patients, caregivers, providers, and payers, to address health barriers. "Exact Sciences is proud to support Walgreens in this preventative health initiative to increase screening rates," said Jake Orville, Executive Vice President and General Manager of Screening, Exact Sciences. "Cologuard tests have made a significant positive impact on screening uptake in the United States and this effort represents an exciting new way to bring the opportunity to screen to patients via their local pharmacy." To learn more about Cologuard tests and colorectal cancer screening options, patients and customers can visit: Cologuard - Noninvasive Colon Cancer Screening | Find Care About Walgreens Founded in 1901, Walgreens (www.walgreens.com) proudly serves more than 9 million customers and patients each day across its nearly 8,000 stores throughout the U.S. and Puerto Rico. Walgreens has approximately 211,000 team members, including roughly 85,000 healthcare service providers, and is committed to being the first choice for pharmacy, retail and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard(R) and Oncotype DX(R), along with innovative solutions like the Cancerguard(R) test for multi-cancer early detection and the Oncodetect(R) test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. About Workflow Services Workflow Services is a software platform that helps pharmacies unlock their full potential as community healthcare destinations. Learn more at www.workflowservices.com References * American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026 * Siegel RL, Wagle NS, Jemal A. Leading Cancer Deaths in People Younger Than 50 Years. JAMA. 2026;335(7):632-634. doi:10.1001/jama.2025.25467 * Itzkowitz SH. Incremental advances in excremental cancer detection tests. J Natl Cancer Inst. 2009;101(18):1225-1227. * Survival rates for colorectal cancer. American Cancer Society. Updated January 29, 2024. Accessed October 9, 2025. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html * Cancer Prevention & Early Detection Facts & Figures, 2025-2026. American Cancer Society. 2025. https://www.cancer.org/research/cancer-facts-statistics/cancer-prevention-early-detection.html SOURCE Workflow Services This is a paid placement. For further inquiries, please contact PR Newswire directly.
KeyCare, the nation’s first Epic-based virtual care company, today announced the close of a $27.4M financing round. The most recent round was led by HealthX ...
KeyCare, the first Epic-based virtual care company, has raised $27.4 million in a financing round led by HealthX Ventures, bringing total capital raised to over $55 million. Participants include 8VC, LRVHealth, BOLD Capital Partners and strategic partners such as WellSpan Health, Allina Health and University of Chicago Ventures. The company operates a 24/7 virtual care medical group providing urgent, preventive, chronic and primary care whilst maintaining integration with patients' home health systems. KeyCare works on an optimised instance of Epic's platform to preserve continuity across the care journey. The funding will support AI-enabled technology development, operational expansion and platform scaling to improve patient experience and provider efficiency. KeyCare aims to create what industry observers call "Telehealth 2.0" by combining Epic's AI capabilities with proprietary AI development.